Kornimate/medical-research-clean huggingface dataset:
class iv versus class iiib laser therapy on median sternotomy healing after coronary artery bybass graft

Conditions: Wound; Wound Heal; Wound Infection

Summary: laser therapy is potent physiotherapy modalities, providing better sternotomy healing for patients who have undergone cabg surgery, compared with traditional wound care management alone. hllt and lllt were found to be the most effective methods for sternotomy healing post-cabg surgery, with hllt offering superior performance in the case of the high deep penetration and significance less time needed to deliver the same joules/ cm compared to lllt used for the wound site.

the aim of this study was to investigate the effects of class iv high-level laser therapy (hllt) versus class iiib low level laser therapy (lllt) on sternotomy healing following coronary artery bypass grafting (cabg) surgery. forty- five patients male patients who had cabg surgery in the age range of 45-65 years were divided randomly into three equal groups (n = 15). the group hllt laser received hllt plus traditional wound management, while the group lllt laser received lllt plus traditional wound management. the control group only received a traditional wound management in form of saline irrigation, dressing, and topical bivatracin spray according to hospital protocol. all groups were offered 10 sessions over 4 weeks. hllt and lllt were found to be the most effective methods for sternotomy healing post-cabg surgery, with hllt offering superior performance in the case of the high deep penetration and significance less time needed to deliver the same joules/ cm compared to lllt used for the wound site.

Eligibility criteria:
inclusion criteria: * aged between 45 and 65 years * male gender; haemodynamic stability * body mass index (bmi) from 18.5 to 29.9 kg/m2 * non-infected sternotomy site * normal ejection fraction to ensure normal vascularity. exclusion criteria: * included previous thoracic surgery * emergency or urgent coronary artery bypass surgery * respiratory insufficiency after surgery, manifesting hypoxemia with partial oxygen pressure in arterial blood \< 60 mmhg; ejection fraction \< 50% * paramedian sternotomy which may cut wire causing sternal mobilization which is the start of deep wound infection * bilateral mammary harvesting which decrease blood flow to sternum; low cardiac output syndrome with st segment elevation in multiple electrocardiogram leads, cardiac arrhythmias or hypotension, according to the american college of cardiology foundation and american heart association * other medical conditions, such as diabetes, uncontrolled hypertension and obesity.

Keywords: coronary arteries bypass grafting high level laser therapy low-level laser therapy median sternotomy healing
development and validation of a simple diagnostic tool predictive of the aseptic character of joint effusion

Conditions: Joint Effusion; Septic Arthritis; Arthritis

Summary: development and validation of a simple diagnostic tool predictive of the aseptic character of joint effusion in the primary care setting.

in accordance with guidelines and because of the potential gravity that this situation could represent, any joint effusion must be considered as a septic arthritis until proven otherwise, thus justifying an arthrocentesis and an adequate treatment. nevertheless, because of epidemiology in primary care, this pragmatic attitude is quite commonly obscured and practices vary according to the experience of the doctor and his personal habits. as a result, the arthrocentesis is not commonly performed and anti-inflammatory treatment, whether based on nsaids or corticosteroids, is even sometimes administered to the patient despite the contrary guidelines. although usually effective, this attitude is however not without risks. in this context, it seems interesting to develop a simple, reproducible and applicable diagnostic tool in a primary care setting for predicting the risk of septic arthritis. this study is therefore aimed at the development and validation of a predictive score based on simple clinical and paraclinical data (such as the macroscopic appearance of the synovial fluid removed) in a patient with an effusion, whatever either the clinical presentation, whether isolated or integrated in a more complex clinical presentation, whether associated with locoregional inflammatory or general signs or not.

Eligibility criteria:
inclusion criteria: * adult patient (age ≥ 18 years) * hospitalized in the conventional hospitalization unit or day hospitalization unit or received in consultation within the rheumatology or infectious diseases units at the le mans general hospital * presenting at least one joint effusion at clinical examination * interesting a native, nonoperated joint, accessible to a puncture based on clinical markers, determined by palpatory anatomy * affiliated to social security * no opposition expressed after written information exclusion criteria: * general antibiotic therapy in progress or completed less than 15 days before * failure to perform the arthrocentesis * person subject to a legal protection measure, not allowing his compliance with the study * participant already included in another study (exclusivity clause)
clinical follow-up and outcomes of pregnancies exposed to ella

Conditions: Emergency Contraception

Summary: the study is aimed at assessing the clinical follow-up and the outcomes of pregnancies exposed to ella, whether due to failure of the emergency contraception or inadvertent exposure during pregnancy.


Eligibility criteria:
* pregnant women, exposed to ella during the menstrual cycle in which the pregnancy started (treatment failure) or at any time during pregnancy (inadvertent exposure during pregnancy) * adolescents and/or adults in the usa, depending on the respective state law

Keywords: ella ulipristal acetate pregnancy emergency contraception
efficacy and safety of curcumin formulation in alzheimer's disease

Conditions: Alzheimer Disease

Summary: curcumin is shown to impact several different pathways of neuroprotection, however clinical trials have not shown positive results, due to the poor bioavailability of curcumin. this study is designed to determine efficacy and safety of high-bioavailability curcumin formulation (longvida) in subjects with alzheimer's disease.

curcumin is a polyphenolic molecule that comprises approximately 3-5% of turmeric (curcuma longa) root, giving the spice its characteristic yellow color. because of its anti-inflammatory, anti-amyloid, and antioxidant properties, curcumin has shown positive effects in animal models of alzheimer's disease (ad). however, a six month human study was conducted with unformulated curcumin showing insignificant trends, due to limited bioavailability and brain permeability of unformulated curcumin. in animal models of ad, oral dosing of solid-lipid curcumin particle (slcp or longvida) significantly reduced memory deficit and impacted biomarkers better than unformulated curcumin. this study is to determine the potential efficacy and safety of highly absorbed slcp curcumin in subjects with ad.

Eligibility criteria:
inclusion criteria: * male or female age ≥ 50. * diagnosed with probable ad using ninds-adrda research criteria. mmse score ≥5 and ≤20. * no history of significant psychiatric or non-ad neurological disease. * an available caregiver to monitor and administer medication and to accompany the subject to every clinical visit. * on stable doses of concomitant medications for at least one month prior to starting study medication. exclusion criteria: * current or recent major psychiatric illness that meets dsm-iv criteria (i.e. bipolar disorder, schizophrenia). * significant uncontrolled systemic illness (i.e. chronic renal failure, chronic liver disease, poorly controlled diabetes, or poorly controlled congestive heart failure). * recent history of gastrointestinal bleeding or ulceration. * alcoholism or substance abuse within the past year per dsm-iv criteria. * familial, autosomal dominant alzheimer's disease due to a mutation in a known gene (presenilin-1, presenilin-2, or amyloid precursor protein).

Keywords: curcumin alzheimer's longvida dementia
investigation of preoperative frailty in elderly patients with colorectal cancer and correlation between preoperative frailty and early postoperative prognosis

Conditions: Colorectal Cancer

Summary: to investigate and analyze the status of preoperative frailty and its influencing factors in elderly patients with colorectal cancer using frall scale and other related scales, and to explore the correlation between preoperative frailty and early prognosis in elderly patients with colorectal cancer, so as to attract the attention of medical staff to preoperative frailty in this population and provide a preliminary research basis for the study of frailty intervention in these patients.


Eligibility criteria:
inclusion criteria: 1. age ≥60 years old; 2. colorectal cancer was diagnosed according to the chinese guidelines for diagnosis and treatment of colorectal cancer (2020 edition) and planned to undergo elective laparoscopic radical resection of colorectal cancer; 3. able to complete physical assessment without communication barriers; 4. voluntarily participated in this study after informed consent. exclusion criteria: 1. taking antidepressants, levodopa, donepezil hydrochloride and other drugs; 2. patients with preoperative colorectal cancer surgery or neoadjuvant therapy; 3. patients with tnm stage ⅳ; 4. complicated with other malignant tumors except primary skin cancer or melanoma.
treatment and biomarker testing patterns,treatment outcomes in a/m nsclc with and without actionable genomic alterations

Conditions: Non-small-cell Lung Cancer

Summary: planned study population consists of approximately 1500 adult patients with a/m nsclc in russia, in about 20 oncological centers (in each center it is expected to recruit about 75 patients) in different regions of russia in order to provide representative study sample


Eligibility criteria:
inclusion criteria: 1. morphologically confirmed nsclc with or without actionable genomic alterations (aga, i.e. egfr, alk, ros1, ntrk, braf, met exon 14 skipping, ret, erbb2 (her2), or kras) 2. age ≥18 years at the time of nsclc diagnosis; 3. locally advanced or metastatic disease defined as incident stage iiib/iiic/iv nsclc or stage i-iiia then progressed to stage iiib-iv disease and not eligible for curative-intent treatment (the date of progression is included in the database); 4. available data on at least one line of systemic therapy for advanced/metastatic disease within the period since january 2022 until january 2025; 5. patients may be alive or deceased at the time of medical record abstraction exclusion criteria: 1. patients participated or participating in clinical trials or any early access program within period since the index date until the end of study period; 2. diagnosis of another cancer (except for melanoma/skin cancer) at or within 5 years prior to nsclc diagnosis or any ongoing systemic anti-cancer therapy regimen at the time of nsclc diagnosis
a phase 1, dose-escalation study of [225ac]-fpi-2068 in adult patients with advanced solid tumours

Conditions: Advanced Solid Tumor; Metastatic Colorectal Carcinoma; Head and Neck Squamous Cell Carcinoma; Non-small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma

Summary: this is a first-in-human, phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (pk) of \[225ac\]-fpi-2068, \[111in\]-fpi-2107, and fpi-2053 in metastatic and/or recurrent solid tumors (hnscc, nsclc, mcrc, pdac).

the study will be conducted in 2 parts: part a: optimization of the fpi-2053 dose (treatment with dose level 1 of \[225ac\]-fpi-2068 - fixed dose). part b: dose escalation of \[225ac\]-fpi-2068 with optimal fpi-2053. part b will commence once the optimal dose of fpi-2053 is determined in part a. the rp2d will be determined from part b based on all available safety, efficacy, pk, and dosimetry information.

Eligibility criteria:
key inclusion criteria: histologically and/or cytologically confirmed solid tumor that is metastatic, locally advanced, recurrent or inoperable. disease that has progressed despite prior treatment, and for which additional effective standard therapy is not available or is contraindicated, not tolerable, or the participant refuses standard therapy. measurable disease as defined by recist version 1.1 ecog performance status of 0 or 1 adequate organ function key exclusion criteria: previous treatment with any systemic radiopharmaceutical prior anti-cancer therapy unless adequate washout and recovery from toxicities contraindications to or inability to perform the imaging procedures required in this study radiation therapy (rt) within 28 days prior to the first dose of \[111in\]-fpi-2107 uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (≥ once per month) patients with known cns metastatic disease unless treated and stable

Keywords: fpi-2068 fpi-2107 fpi-2053 fpi-1784 actinium-225 225ac indium-111 111in solid tumors targeted alpha therapy tat epidermal growth factor receptor egfr mesenchymal-epithelial transition factor cmet bispecific antibody radioimmuno-spect agent radioimmuno-therapeutic agent monoclonal antibody bifunctional chelating agent radiopharmaceutical therapy alpha particle emitter directed bispecific monovalent antibody bsab bifunctional chelate mcrc hnscc nsclc pdac rlt radioligand therapy egfrm egfrwt
musculoskeletal disorders and the associated factors of healthcare professionals

Conditions: Musculoskeletal Disorders; Psychosocial Problem

Summary: the aim is to assess the prevalence of musculoskeletal disorders among italian health professionals by analysing demographic and psychosocial factors. in addition, the impact of the symptoms detected on the quality of life and physical and mental health was analyzed. all health workers on duty in hospital wards for at least 12 months

the online questionnaire sent to the participants was divided into two sections. the first section concerned the collection of demographic data of the participants (eg age, gender, level of education, work experience, company to which they belong, department, profession, etc.). the second section concerned the assessment of the prevalence of musculoskeletal disorders, pain, quality of life and assessment of subjective perception of health and assessment of psychosocial factors in the workplace.

Eligibility criteria:
inclusion criteria: * health personnel who were active in clinical practice during the study period from january to june 2022. * all health professionals who signed the informed consent * health professionals in service in the wards for at least 12 months from the date of sending the questionnaire. exclusion criteria: health workers with unsuitability for handling loads
chemoreflex sensitivity in hfpef

Conditions: Heart Failure With Preserved Ejection Fraction

Summary: patients with heart failure and a preserved left ventricular ejection fraction (hfpef) almost invariably complain of exertional breathlessness. abnormal cardiac hemodynamics with pulmonary congestion are believed to trigger dyspnea in this patients. however, some patients may complain of exertional breathlessness which seems to be out of proportion as compared with hemodynamic abnormalities. chemoreflex sensitivity accounts for the ventilatory responses to a variety of chemical stimuli, including carbon dioxide produced by the organism during exercise. chemoreflex sensitivity can be augmented in heart failure with reduced left ventricular ejection fraction, and an increased chemoreflex sensitivity has been linked to symptoms, neurohumoral activation, breathing disturbances, and adverse prognosis. however, the clinical correlates and implications of chemoreflex sensitivity in hfpef have not been accurately studied. we aim to characterize chemoreflex sensitivity in patients with a diagnosis of hfpef, and to correlate chemoreflex sensitivity with clinical and hemodynamic characteristics.


Eligibility criteria:
inclusion criteria: * diagnosis of symptomatic hfpef (group 1) * diagnosis of asymptomatic left ventricular diastolic dysfunction with echocardiographic signs of ph (group 2) * healthy volunteers (group 3) exclusion criteria: * breastfeeding or childbearing
specific modified exercise program for patients having chronic asthma

Conditions: Asthma

Summary: to compare the effects of moderate intensity interval training and sprint interval training on patients having chronic asthma.

chronic asthma is a complex heterogeneous disease characterized by multiple aggravating factors. asthma is treated with two types of medicines , long term medicines and quick relieve medicine. although the relationship between asthma and the effects of hiit/sit were studied in the literature, there was not one comparing the results of these aforementioned studies. the purpose of this study is to find the effects of moderate intensity interval training and sprint interval training on pat determine effects of group wise physical activity on asthma related quality of life. to determine the effects of group wise physical activity on cardiorespiratory endurance

Eligibility criteria:
inclusion criteria: * patients having chronic asthma * age between 15-25 years. * participants having no dyspnea at rest . * participants scoring 13 or less on borg scale * exclusion criteria * history of co-morbidities. * history of recent fractures. * participants scoring greater than 13 on borg scale exclusion criteria: * exercise induced asthma (evaluated through bruce protocol). * individuals with co-morbidities related to any neurological, cardiovascular, psychological and musculoskeletal disorders . * patients score falling 15 or more on borg scale.
clinical study of an ultrasound renal denervation system in patients with heart failure

Conditions: Chronic Heart Failure

Summary: the purpose is to evaluate the renal denervation system (prds-001) for controlling sympathetic nerve over-activation in patients with heart failure, and for its safety in such patients.


Eligibility criteria:
inclusion criteria : * patients aged 18 years or older and younger than 85 years at the time of informed consent * nyha (new york heart association) class ii-iii * more than 6 weeks have passed since onset of acute heart failure or acute exacerbation of chronic heart failure * washout rate of mibg \[3 (meta)-iodobenzylguanidine\] scintigraphy-cardiac is more than 35% * patients having continued treatment of heart failure with the same dosage and administration for 4 weeks before obtaining informed consent exclusion criteria : * patients with type1 diabetes mellitus, or uncontrolled type 2 diabetes mellitus (hba1c: ≥ 8%) * patients whose egfr (estimated glomerular filtration rate) is less than 40 ml/min/1.73 m\^2 (estimation formula by japanese society of nephrology) * patients with concomitant or previous autoimmune or inflammatory bowel disease * patients with a history of serious lung disease * patients with a history of heart transplantation or vad \[ventricle-assist device\] * patients receiving reserpine, tricyclic antidepressants, and labetalol hydrochloride (can be used for up to 5 half-lives before informed consent is obtained) * patients being treated for parkinson's disease or lewy body dementia * patients with a history of any severe cardiovascular event (myocardial infarction, coronary artery bypass graft surgery, acute heart failure requiring hospitalization) or severe cerebrovascular event (stroke, transient ischemic event, cerebrovascular accident, etc.) within 3 months before obtaining informed consent * patients with persistent atrial fibrillation * patients using active implantable medical devices * patients with coronary or carotid artery diseases who were deemed necessary by the principal investigator / sub investigator to undergo surgery or pci (percutaneous coronary intervention) within 6 months after obtaining informed consent * patients with contraindications, unacceptable anaphylactic reactions, or uncontrollable allergies to contrast media * female patients who are pregnant or breastfeeding * patients whose office blood pressure (systolic) is 100mmhg or lower at the time of screening test

Keywords: denervation renal denervation heart failure ultrasound cardiovascular diseases
study for determination of feasibility and toxicity of pre-treatment with hpph (2-1[1-hexyloxyethyl]-2 devinyl pyropheophorbide-a) photodynamic therapy prior to chemoradiation in non-operable patients with obstructive esophageal cancer

Conditions: Esophageal Neoplasm

Summary: this study aim is to find out what effects capecitabine, oxaliplatin and radiation therapy following photodynamic therapy have on esophageal cancer.


Eligibility criteria:
inclusion criteria: * partially or completely obstructing primary esophageal carcinoma, clinical stage i-iva as determined by endoscopy, ct-scan, pet +/- endoscopic ultrasound. for distal esophagus tumors involving the ge junction, at least 50% or greater of the tumor bulk should be in the distal esophagus * ineligible for or refused surgical resection * no prior therapy allowed for esophageal cancer * ecog performance status 0-1 * life expectancy \> 4 months * adequate hematologic parameters (hemoglobin\> 9g/dl, anc \> 1500/ul, platelets \> 100,000/ul) * adequate biochemical parameters (total bilirubin and creatinine within institutional limits, ast and alkaline phosphatase less tham or equal to 3xunl) * age \> 18 years * signed informed consent * bronchoscopy with biopsy and cytology if primary esophageal cancer is \< 26 cm from incisors * female patients of childbearing potential should have a negative serum or urine pregnancy test within 7 days prior to registration * patients of childbearing potential agree to use an effective form of contraception during the study and for 90 days following the last dose of study medication (an effective form of contraception is an oral contraceptive or a double barrier method * both men and women and members of all races and ethnic are eligible for this trial exclusion criteria: * hypersensitivity to platinum compounds, fluoropyrimidines or to antiemetics appropriate for administration in conjunction with protocol-directed chemotherapy * patients may not be receiving any other investigational agents * patients with known brain metastases should be excluded from this trail * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social situations that would limit compliance with study requirements * peripheral neuropathy ≥ grade 2 * history of second malignancy within the previous years except for curatively treated carcinoma of the cervix in-situ or non-melanomatous skin cancer * patients who are pregnant or lactating * porphyria or hypersensitivity to porphyrin-like compounds * patients with known hiv or hepatitis b or c (active, previously treated or both) * patients with tracheal or bronchial involvement, as determined by bronchoscopy * patients with documented unilateral or bilateral vocal cord paralysis * patients with t4 lesions by ct, mri or eus involving the aorta, lung or pericardium

Keywords: obstructing